{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:33:26Z","timestamp":1793741606253,"version":"4.6.1"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson\u2019s disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of GLP-1 RAs in PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of randomized placebo-controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE and Scopus databases was conducted on October 7, 2025, for randomized placebo-controlled clinical trials investigating GLP-1 RAs in adults with PD. Risk of bias was evaluated using the Cochrane Collaboration risk-of-bias (RoB2) tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Four RCTs comprising 667 PD patients (377 receiving GLP-1 RAs) were included. Between baseline and end-of-treatment, no differences were observed in the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) Part III score change between GLP-1 RA- and placebo-treated patients in either off-medication (standardized mean difference (SMD): \u22120.16; 95% CI: \u22120.64 to 0.32;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.52) or on-medication states (SMD: \u22120.13; 95% confidence interval (CI): \u22120.51 to 0.25;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.49). No significant differences were uncovered in other MDS-UPDRS subscores, Non-Motor Symptoms Scale, Montreal Cognitive Assessment, or Parkinson\u2019s Disease Questionnaire scores. The risk of serious adverse events and odds of treatment discontinuation were similar between groups, but GLP-1 RAs were associated with an increased risk of weight loss compared to placebo (risk ratio: 1.44; 95% CI: 1.04\u20131.99;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GLP-1 RAs were not associated with improvements in motor or non-motor domains of PD. However, robust preclinical evidence and promising findings in select subpopulations warrant further RCTs to evaluate their neuroprotective potential, prioritizing long-acting and brain-penetrant agents that effectively engage central GLP-1 circuits for PD treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>The pre-specified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD420251008703).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251408269","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:45:57Z","timestamp":1769863557000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson\u2019s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-6627","authenticated-orcid":false,"given":"Maria-Ioanna","family":"Stefanou","sequence":"first","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Neurology and Stroke, Eberhard-Karls University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Panagiotopoulos","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tentolouris","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-2610","authenticated-orcid":false,"given":"Aikaterini","family":"Theodorou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Papagiannopoulou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Athanasaki","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota-Eleni","family":"Tsalouchidou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Peppa","sequence":"additional","affiliation":[{"name":"Diabetes Center, Second Department of Internal Medicine, \u201cAttikon\u201d University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[{"name":"Diabetes Center, Second Department of Internal Medicine, \u201cAttikon\u201d University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiridon","family":"Konitsiotis","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-3020","authenticated-orcid":false,"given":"Annerose","family":"Mengel","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke, Eberhard-Karls University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios P.","family":"Paraskevas","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tentolouris","sequence":"additional","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-3797","authenticated-orcid":false,"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, \u201cAttikon\u201d University Hospital, School of Medicine, National and Kapodistrian University of Athens, Rimini 1, Chaidari, Athens 12462, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30295-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00378-2"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"e_1_3_4_6_2","article-title":"Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice","volume":"163","author":"Grunddal KV","year":"2022","unstructured":"Grunddal KV, Jensen EP, \u00d8rskov C, et al. Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice. Endocrinology 2022; 163: bqab216.","journal-title":"Endocrinology"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2011.8.418"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0956-9"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00681-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.01.013"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0051-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.06.054"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100133"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68295"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323"},{"key":"e_1_3_4_16_2","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease","volume":"7","author":"Mulvaney CA","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J, et al. GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev 2020; 7: CD012990.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31585-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2019.1587000"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241281903"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/23969873241234238"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_3_4_24_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovic\u00b4 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/23969873251324863"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.01.006"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174981"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.09.002"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch10"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02808-3"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.06.003"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051987"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15134"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr5051"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.040"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2017.00271"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00724-y"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045272"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163585"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29122"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107220"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13301-y"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01888-1"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1806824"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251372747"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","unstructured":"Hogg E Wu T Bresee C et al. A phase II randomized double-blinded placebo-controlled trial of liraglutide in Parkinson\u2019s disease https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4212371 (2022).","DOI":"10.2139\/ssrn.4212371"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3068"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251408269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251408269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251408269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:20:10Z","timestamp":1769977210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251408269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"alternative-id":["10.1177\/17562864251408269"],"URL":"https:\/\/doi.org\/10.1177\/17562864251408269","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"17562864251408269"}}